-transparent.png){kind=logo}
This report is the result of an Eastern Cooperative Oncology Group (ECOG) study. Four hundred and 15 patients with inoperable metastatic malignant melanoma, excluding those with cutaneous metastases only, were randomized to one of three drug treatments: DTIC alone, methyl-CCNU alone, or the combination DTIC plus methyl-CCNU. Responses were seen in 14% of DTIC patients (19/127), 15% of methyl-CCNU patients (18/119) and 14% of DTIC plus methyl-CCNU patients (18/122). Duration of response was the same (14 weeks) for all three treatment groups. There was no difference among the treatments in achieving complete responses. Survival was improved significantly for responders (50 weeks) compared with nonresponders (15 weeks) regardless of treatment regimen. Toxicities were generally tolerable. DTIC caused significantly more gastrointestinal toxicity than methyl-CCNU. Methyl-CCNU caused significantly more bone marrow toxicity than DTIC. There were three drug-related deaths. All occurred in patients on combination DTIC plus methyl-CCNU. Important pretreatment characteristics that favor response are ambulatory status, female, less than 50 years old, no prior chemotherapy and no liver or brain metastases. Patients with favorable characteristics combinations had a 30% response rate, while those with unfavorable characteristic combinations had only a 9% response rate.
M E Costanza, and
L Nathanson, and
D Schoenfeld, and
J Wolter, and
J Colsky, and
W Regelson, and
T Cunningham, and
N Sedransk
December 1980,
Cancer,
M E Costanza, and
L Nathanson, and
D Schoenfeld, and
J Wolter, and
J Colsky, and
W Regelson, and
T Cunningham, and
N Sedransk
August 1977,
Cancer treatment reports,
M E Costanza, and
L Nathanson, and
D Schoenfeld, and
J Wolter, and
J Colsky, and
W Regelson, and
T Cunningham, and
N Sedransk
December 1977,
Cancer treatment reports,
M E Costanza, and
L Nathanson, and
D Schoenfeld, and
J Wolter, and
J Colsky, and
W Regelson, and
T Cunningham, and
N Sedransk
January 1979,
Cancer treatment reports,
M E Costanza, and
L Nathanson, and
D Schoenfeld, and
J Wolter, and
J Colsky, and
W Regelson, and
T Cunningham, and
N Sedransk
November 1992,
The British journal of dermatology,
M E Costanza, and
L Nathanson, and
D Schoenfeld, and
J Wolter, and
J Colsky, and
W Regelson, and
T Cunningham, and
N Sedransk
November 1980,
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
M E Costanza, and
L Nathanson, and
D Schoenfeld, and
J Wolter, and
J Colsky, and
W Regelson, and
T Cunningham, and
N Sedransk
June 1974,
Clinical pharmacology and therapeutics,
M E Costanza, and
L Nathanson, and
D Schoenfeld, and
J Wolter, and
J Colsky, and
W Regelson, and
T Cunningham, and
N Sedransk
January 1979,
Cancer treatment reports,
M E Costanza, and
L Nathanson, and
D Schoenfeld, and
J Wolter, and
J Colsky, and
W Regelson, and
T Cunningham, and
N Sedransk
January 1984,
Investigational new drugs,
M E Costanza, and
L Nathanson, and
D Schoenfeld, and
J Wolter, and
J Colsky, and
W Regelson, and
T Cunningham, and
N Sedransk
May 1989,
Cancer,
